A New Jersey overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
More than one in four adults in New Jersey — 27.7%, per the CDC's 2024 BRFSS release 4 — live with obesity. That puts the state among the five lowest rates of any U.S. state or the District of Columbia, trailing only Massachusetts (27.0%), Hawaii (27.0%), D.C. (25.5%), and Colorado (25.0%) 45.
Even at the favorable end of the national range, that is still more than a quarter of adults statewide — a large population, in a state of 9,500,851 residents (Census Vintage 2024) 67, for whom effective treatment, including GLP-1 therapies, is increasingly relevant.
NJ Medicaid (NJ FamilyCare — fee-for-service plus its five managed-care organizations: Aetna, Fidelis, Horizon, UnitedHealthcare, and Wellpoint, covering roughly 1.77 million enrollees as of Q1 2026) is not a flat 'no' on GLP-1 obesity medications. The Division of Medical Assistance & Health Services' Drug Utilization Review Board (DURB) maintains an active, DURB-approved prior-authorization protocol specifically for Wegovy (semaglutide), most recently amended on October 22, 2025 to add a newly FDA-approved MASH indication — meaning the underlying coverage pathway already existed and was live enough to need updating 13.
Diabetes-indicated GLP-1/GIP agents (Ozempic, Mounjaro, Trulicity, Rybelsus) are covered under a separate protocol, and Imcivree (setmelanotide) is covered for genetic/syndromic obesity 1. There is genuine utilization-management friction, though: the 'ADHD/Anti-Narcolepsy/AntiObesity/Anorexiants' prior-authorization category ran an 8–14% denial rate across NJ's five MCOs in Q1 2026, and the DURB itself has an open, unresolved question — still outstanding as of the July 2026 meeting packet — asking MCOs to explain the elevated rate 12.
TODO / data gap: New Jersey has not published the Wegovy protocol's specific BMI, comorbidity, or step-therapy criteria as a standalone document, so no clinical threshold is stated here. Zepbound (tirzepatide's obesity-indication brand) appears only in a utilization-tracking chart in the DURB packet, not in any protocol-addendum action item — its specific prior-authorization criteria are undocumented in the public record reviewed, so its coverage status is unconfirmed, not denied 1.
Utilization is climbing sharply either way: fee-for-service GLP-1/GIP claims rose from 189 per quarter (2023 Q4) to 489 per quarter (2026 Q1), and MCO claims rose from 37,959 to 62,563 over the same span — though most of that volume sits under the diabetes-indication protocol, not the obesity-specific Wegovy protocol 1.
Astra's price in New Jersey is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no New Jersey-specific price, surcharge, or discount.
An 8–14% PA denial rate 1 means a share of NJ FamilyCare enrollees who qualify on paper still end up paying cash; that is the gap flat national pricing is meant to answer.
New Jersey telehealth prescribing is licensed through the New Jersey State Board of Medical Examiners (Division of Consumer Affairs), njconsumeraffairs.gov/bme — an unverified candidate link, not a confirmed citation. TODO: this page has not independently verified New Jersey's current specific telehealth rules — e.g., whether an initial in-person exam is required for controlled-adjacent obesity medications, audio-only visit allowances, or interstate reciprocity terms. Treat any such detail as unconfirmed until it is checked directly against the Board's published regulations.
Astra is licensed in all 50 states, New Jersey included. Astra has no physical clinic in Newark or anywhere else in the state; care is delivered by licensed clinicians over telehealth, with medication shipped to the patient.
Astra treats patients in New Jersey through state-licensed physicians.
Newark is New Jersey's city page under this hub.
Not as a blanket exclusion. NJ Medicaid (NJ FamilyCare fee-for-service plus its five managed-care plans — Aetna, Fidelis, Horizon, UnitedHealthcare, and Wellpoint) runs an active, DURB-approved prior-authorization protocol specifically for Wegovy (semaglutide), most recently updated October 22, 2025. Diabetes-indicated GLP-1/GIP drugs (Ozempic, Mounjaro, Trulicity, Rybelsus) are covered under a separate protocol, and Imcivree is covered for genetic/syndromic obesity. That said, there's real friction: the relevant prior-authorization category ran an 8–14% denial rate across NJ's five MCOs in Q1 2026, and state reviewers have an open, unresolved question — still outstanding as of mid-2026 — about why those rates are elevated. New Jersey has not published Wegovy's specific BMI or comorbidity criteria, and Zepbound's coverage terms aren't documented in the public record we reviewed, so specific approval odds can't be stated here.
No — and we won't pretend otherwise. Astra's pricing is national: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans ($816 and $1,416 billed annually), the same in New Jersey as in every state we serve. If your NJ Medicaid plan approves prior authorization for a GLP-1 obesity medication, that route may cost less out of pocket than paying directly — see the question above. What differs city to city is what's available locally without insurance, not what Astra charges.
At 27.7% (CDC BRFSS, 2024), New Jersey has one of the five lowest adult obesity rates of any U.S. state or D.C. — behind only Massachusetts and Hawaii (27.0% each), Washington D.C. (25.5%), and Colorado (25.0%). It's a relatively favorable rank nationally, but it still means more than one in four New Jersey adults live with obesity.
Telehealth prescribing in New Jersey is licensed through the New Jersey State Board of Medical Examiners. TODO: we have not yet independently verified New Jersey's current specific rules on in-person exam requirements, audio-only visit allowances, or interstate reciprocity — treat any such detail as unconfirmed until checked directly against the Board's published regulations.
No physical clinic is needed — Astra is licensed to treat patients by telehealth in all 50 states, including New Jersey. See our Newark, NJ guide for city-specific numbers, or start an online visit from anywhere in the state.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.